Inhibition of Thymidylate Synthase: Biochemical Pharmacology of Drugs with Activity in Colorectal Cancer

Clendennin N.J. , Collier M.A. , Johnston A.L. , Loh K.K. , Cohn A. , Kelly K. , Globe L.M. , Stuart K.E. , Belani C.P. : Thymitaq^™ (AG337): a novel thymidylate synthase inhibitor with clinical activity in solid tumours. Proc. Am. Assoc. Cancer Res., 37: 171, 1996.

Cunningham D. , Zalcberg J. , Smith I.E. , Gore M. , Pazdur R. , Burris H. III , Azab M. , Kennealey G. : Tomudex: a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann. Oncol., 5(suppl. 8) 179, 1994.

Jackman A.L. , Boyle F.T. , Harrap K.R. : Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Inv. New Drugs, 14: 305–316, 1996.

Jackman A.L. , Farrugia D.C. , Gibson W. , Kimbell R. , Harrap K.R. , Stephens T.C. , Azab M. , Boyle F.T. : ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer, 31A: 1277–1282, 1995.

Jackman A.L. , Judson I.R. : The new generation of thymidylate synthase inhibitors in clinical study. Exp. Opin. Invest. Drugs, 5: 719–736, 1996.

Jackman A.L. , Taylor G.A. , Calvert A.H. , Harrap K.R. : Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol., 33: 3269–3275, 1984.

Jackman A.L. , Taylor G.A. , Gibson W. , Kimbell R. , Brown M. , Calvert A.H. , Judson I.R. , Hughes L.R. , ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study Cancer Res., 51: 5579–5586, 1991.

Johnston P.G. , Lenz H.J. , Leichman C.G. , Danenberg K.D. , Allegra C.I. , Danenberg P.V. , Leichman L. : Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res., 55: 1407–1412, 1995.

Peters G.J. : Antimetabolites. In: The scientific basis for cancer treatment, Oxford textbook of Oncology, Peckham M. , Pinedo H. , Veronesi U. , Eds., pp. 524–552, Oxford University Press, Oxford, 1995.

Schultz R. , Andis S. , Chen V. , Mendelsohn L. , Patel V. , Shih C. , Houghton J. : Comparative antitumour activity of the multitargeted antifolate LY231514 and the thymidylate synthase inhibitor ZD1694. Annals of Oncology, 7(suppl. 1) 85, 1996.

Seitz J.F. , Cunningham D. , Rath U. , Olver I.N. , Van Cutsem E. , Kerr D. , Svensson C. , Perez Manga G. , Harper P. , Zalcberg J. , Lowery K. , Azab M. for the Tomudex’ study group: Final results and survival data of a large randomized trial of Tomudex in advanced colorectal cancer confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU+LV). Proc. Am. Soc. Clin. Oncol., 15: 201, 1996.